| Not Yet Recruiting | Tier Palliative Care For Patients With Advanced Heart Failure or Cancer NCT07391956 | Icahn School of Medicine at Mount Sinai | N/A |
| Recruiting | A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors NCT07227623 | Massachusetts General Hospital | N/A |
| Not Yet Recruiting | The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer With Concurrent Hypertension NCT07261098 | Shanghai Chest Hospital | Phase 2 |
| Not Yet Recruiting | A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection NCT07367529 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer NCT06791057 | Massachusetts General Hospital | N/A |
| Not Yet Recruiting | A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer NCT07309276 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Not Yet Recruiting | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer NCT07110363 | Biotroy Therapeutics | Phase 1 |
| Recruiting | Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursin NCT07405931 | Ulsan University Hospital | N/A |
| Recruiting | Engage Psychosocial Intervention for Cancer Symptoms NCT06555588 | Duke University | N/A |
| Recruiting | A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer NCT07229599 | Minghui Pharmaceutical (Hangzhou) Ltd | Phase 1 / Phase 2 |
| Recruiting | Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer NCT06992583 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 NCT06892548 | BioNTech SE | Phase 1 / Phase 2 |
| Recruiting | Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Posi NCT06945523 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma NCT06903117 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid NCT06928922 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | EARLY_Phase 1 |
| Enrolling By Invitation | Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer NCT06228209 | Icahn School of Medicine at Mount Sinai | N/A |
| Withdrawn | Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures NCT06713798 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Recruiting | A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer NCT06768151 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Not Yet Recruiting | Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC NCT06456138 | Shanghai Chest Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | TIL Therapy for Patients With Advanced Solid Tumors NCT06107894 | NeogenTC | Phase 1 |
| Completed | Family-Supported Palliative Care in Advanced Lung Cancer NCT07490639 | Shanxi Province Cancer Hospital | N/A |
| Unknown | WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody NCT06106152 | Second Affiliated Hospital, School of Medicine, Zhejiang University | EARLY_Phase 1 |
| Completed | A Clinical Study of Pain and Discomfort Associated With Advanced Lung Cancer NCT05852002 | Nakhia Impex LLC | N/A |
| Completed | Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer NCT05815862 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Completed | JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer NCT05664971 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Evidence-Based Nursing Plus Progressive Exercise for Cancer-Related Fatigue in Advanced Lung Cancer NCT07498972 | Shanxi Province Cancer Hospital | N/A |
| Unknown | Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Ad NCT06326086 | Prince of Songkla University | — |
| Unknown | A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer NCT05431569 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 |
| Unknown | The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer. NCT05279521 | National Taiwan University Hospital | N/A |
| Unknown | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 NCT05805956 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 1 / Phase 2 |
| Completed | Study of JS004 Combined With Toripalimab for Advanced Lung Cancer NCT05000684 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC NCT04672369 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Completed | A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patient NCT04672356 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Unknown | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer NCT04670445 | Massachusetts General Hospital | N/A |
| Completed | Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator NCT04352335 | Chung Shan Medical University | — |
| Recruiting | A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer NCT06183762 | Hunan Province Tumor Hospital | — |
| Completed | Descriptors and Predictors of Burden and Information Needs NCT04069494 | Chulabhorn Cancer Center | — |
| Completed | Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL) NCT04575831 | University of Calgary | N/A |
| Unknown | Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer NCT03751592 | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | Phase 1 / Phase 2 |
| Withdrawn | MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) NCT03004105 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer NCT03501056 | Fuda Cancer Hospital, Guangzhou | Phase 2 |
| Terminated | CAR-T Cell Immunotherapy for Advanced Lung Cancer NCT03330834 | Sun Yat-sen University | Phase 1 |
| Unknown | Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer NCT02862587 | Shanghai International Medical Center | Phase 1 / Phase 2 |
| Unknown | Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer NCT02873416 | Ningbo Cancer Hospital | Phase 1 / Phase 2 |
| Completed | Enhancing Quality of Life in Patients (EQUIP) Intervention for Patients With Advanced Lung Cancer NCT02801734 | National Cancer Centre, Singapore | N/A |
| Terminated | Cambridge Brain Mets Trial 1 NCT02768337 | Cambridge University Hospitals NHS Foundation Trust | Phase 1 / Phase 2 |
| Terminated | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advan NCT02109016 | Clovis Oncology, Inc. | Phase 2 |
| Completed | Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers NCT01579994 | Memorial Sloan Kettering Cancer Center | Phase 1 |